Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
sNN0029 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| sNN0029 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| sNN0029 | DRUG | Continuous ICV infusion at one of three dose levels |
| Placebo | DRUG | Continuous ICV infusion |
Inclusion Criteria: 1. Clinical diagnosis of ALS classified as definite, or probable with or without additional laboratory evidence, according to the revised WFN El Escorial criteria. 2. Age 18 to 75 years inclusive. 3. If patients are being treated with riluzole, they must have been on a stable do...
sNN0029 is an investigational small molecule being studied for the treatment of Amyotrophic Lateral Sclerosis (ALS). It is administered via intracerebroventricular delivery, meaning it is given directly into the cerebrospinal fluid. The drug is currently in clinical development and has not been approved by regulatory authorities.
sNN0029 is being developed by Medtronic plc, a medical technology company traded on the New York Stock Exchange under the ticker MDT. The company is conducting clinical trials to evaluate the safety and tolerability of sNN0029 in patients with Amyotrophic Lateral Sclerosis.
sNN0029 is in Phase 1 clinical development. It has completed one Phase 1 trial, which was a randomized, double-blind, placebo-controlled study. The drug remains investigational and is not yet approved for any use.
sNN0029 has one completed clinical trial registered as NCT00800501. This Phase 1 study evaluated the safety and tolerability of intracerebroventricular administration of sNN0029 in patients with Amyotrophic Lateral Sclerosis. The trial enrolled 18 participants and was conducted in Belgium.
No alternative names for sNN0029 have been identified. The drug is known only by its development code sNN0029, and no other names or aliases have been associated with it in clinical trial registrations or development records.